Masimo is a medical technology company that develops, manufactures, and markets a variety of noninvasive monitoring technologies. The company provides its products to hospitals, emergency medical service providers, long-term care facilities, physician offices, veterinarians and consumers. The company's main business is Measure-through Motion and Low Perfusion? pulse oximetry monitoring, known as Masimo Signal Extraction Technology? pulse oximetry. The company's products offerings also includes noninvasive monitoring of blood constituents with an optical signature, optical organ oximetry monitoring, electrical brain function monitoring, acoustic respiration monitoring and exhaled gas monitoring.
  • TickerMASI
  • ISINUS5747951003
  • ExchangeNASDAQ Stock Market
  • SectorHealth Care Equipment & Services
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for MASI

ValuEngine Rating and Forecast Report for MASI

ValuEngine Rating and Forecast Report for MASI

ValuEngine Rating and Forecast Report for MASI

ValuEngine Rating and Forecast Report for MASI

ValuEngine Rating and Forecast Report for MASI

MASIMO CORP. sees a downgrade to Slightly Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of MASIMO CORP. (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date September 10, 2019, the closing price was USD 145.61 and its target price was estimated at USD 129.56.

ValuEngine Rating and Forecast Report for MASI

ValuEngine Rating and Forecast Report for MASI

Jake Strole

Morningstar | Masimo Continues to Gain Market Share, Supporting its Positive Moat Trend Rating

Masimo has established itself at the forefront of algorithms and sensor technologies for patient monitoring through the development of its proprietary signal extraction technology, or SET, for use in pulse oximetry and other measurement applications. The SET platform remains leagues ahead of competing products in terms of accuracy and reliability, leading to extremely sticky customer relationships and meaningful pricing power. Masimo has developed a hybrid go-to-market model that has allowed for the proliferation of its SET and next-generation rainbow SET measurement parameters through direct ...

Jake Strole

Masimo Continues to Gain Market Share, Supporting its Positive Moat Trend Rating

Narrow-moat Masimo reported first-quarter financials that were in line with our expectations, although better-than-expected growth in driver placement sets the stage for continued strength throughout the remainder of the year. As we tweak our model we'll likely raise our $130 per share fair value estimate by a mid-single-digit percentage, but largely view shares as fairly valued in the market following sizable outperformance over the last year. While changes in accounting standards created some ...

Jake Strole

Morningstar | Masimo Beats and Raises to Start 2019; Bumping FVE

Narrow-moat Masimo reported first-quarter financials that were in line with our expectations, although better-than-expected growth in driver placement sets the stage for continued strength throughout the remainder of the year. As we tweak our model we'll likely raise our $130 per share fair value estimate by a mid-single-digit percentage, but largely view shares as fairly valued in the market following sizable outperformance over the last year. While changes in accounting standards created some revenue and gross profit comparability issues, product revenue grew approximately 13.1% in constant...

Jake Strole

Masimo Beats and Raises to Start 2019; Bumping FVE

Narrow-moat Masimo reported first-quarter financials that were in line with our expectations, although better-than-expected growth in driver placement sets the stage for continued strength throughout the remainder of the year. As we tweak our model we'll likely raise our $130 per share fair value estimate by a mid-single-digit percentage, but largely view shares as fairly valued in the market following sizable outperformance over the last year. While changes in accounting standards created some ...

Jake Strole

Morningstar | Masimo Remains on Track to Strengthen Its Economic Moat in 2019

Masimo has established itself at the forefront of algorithms and sensor technologies for patient monitoring through the development of its proprietary signal extraction technology, or SET, for use in pulse oximetry and other measurement applications. The SET platform remains leagues ahead of competing products in terms of accuracy and reliability, leading to extremely sticky customer relationships and meaningful pricing power. Masimo has developed a hybrid go-to-market model that has allowed for the proliferation of its SET and next-generation rainbow SET measurement parameters through direct ...

A director sold 11,000 shares at 87.250USD and

A director at Masimo Corp sold 11,000 shares at 87.250USD and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of bo...

ValuEngine Rating and Forecast Report for MASI

ValuEngine Rating and Forecast Report for MASI

ValuEngine Rating and Forecast Report for MASI

ValuEngine Rating and Forecast Report for MASI

ValuEngine Rating and Forecast Report for MASI

ValuEngine Rating and Forecast Report for MASI

MASIMO CORP. sees a downgrade to Slightly Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of MASIMO CORP. (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date September 10, 2019, the closing price was USD 145.61 and its target price was estimated at USD 129.56.

ValuEngine Rating and Forecast Report for MASI

ValuEngine Rating and Forecast Report for MASI

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • A few Consumer Discretionary names continue to act well. The list is thinning of attractive names though. (ex. FOXF, UEIC, DECK, CHDN, WING, YUM, BOOT, RCI, POOL, DLTR, and AAN) • A number of Health Care Sector names are attractive. (ex. MASI, TFX, CNMD, STE, CRVL, LNTH, HAE, COO, WST, RGEN, ANIK, NEO, and TECH) • Attractive Technology and Services names include: MANH, CDNS, ANSS, AGYS, TTEC, CLGX, MMS, and KBR

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • Health Care Equipment & Supplies remains a leadership area in the Health Care Sector. • A number of Biotechnology stocks are making major reversals with many hitting 52-week RS highs. • Semiconductors, Semi-Suppliers, and Electronic Components remain as leadership Groups.

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: Biotech continues to be leadership Shoe retailers are leadership in Consumer Discretionary A few Trucking stocks are near reversals

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • Health Care remains a bright spot and many individual names are breaking to RS highs. • Many Consumer Cyclical names such as NKE and CMG are emerging as leadership. • Many Semi and Semiconductor supplier names are staging Price and RS reversals.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch